Sodium–glucose cotransporter 2 (SGLT2) inhibitors [15,16], nonsteroidal mineralocorticoid receptor antagonists (MRAs) [17], and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [18] have emerged as cardiorenal disease-modifying therapies for the prevention of the DKD progression. Here, GLP1R is linked to diabetic kidney disease.